Tag : GWPH

Current News Market Watch Uncategorized

GW Pharmaceuticals Receives Approval for 5 New Patents for Epidiolex

Editor
GW Pharmaceuticals (Nasdaq:GWPH) recently announced that their company has received “Notices of Allowance” from the United States Patent and Trademark office for five new Epidiolex® patent applications for the company’s proprietary Cannabidiol (CBD) based pharmaceutical. Epidiolex® is concentrated on treating rare, treatement resistant epilepsy conditions such as Dravet syndrome, Lennox-Gastaut...
Cash Crop 150 CCT Voice

Top 10 Public Companies with the Largest Market Caps in Cannabis

Editor
10. Emerald Health Therapeutics Inc. (TSX: EMH) $674 Million Emerald Health Therapeutics, Inc. operates through Emerald Health Therapeutics Canada Inc. (“EHTC”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for...
Current News Market Watch Uncategorized

GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA)

Editor
On February 27, 2018, GW Pharmaceuticals, PLC (Nasdaq:GWPH) (“GW) announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW has started a Phase 3 clinical trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of...
Current News Health

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

Editor
On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s...